Gilead Sciences, Inc.
GILD· Nasdaq
GILDGilead Sciences, Inc.
Filed Feb 23, 2024 · 10-K · 54 days after period end · 0000882095-24-000007
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $7.11B | $7.39B | $7.24B | $7.42B |
| Net Income | $1.43B | $1.64B | $382.00M | $1.55B |
| EPS Diluted | — | — |
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
| — |
| $1.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 23, 2024 · 54 d after period end
